Filing Flows › Sunshine Biopharma (SBFM) › Q2 2025
Sunshine Biopharma (SBFM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Sunshine Biopharma (SBFM) reported revenue of $9.4M for the second quarter 2025 (Q2 2025), +1% from a year earlier and +6% from the quarter before. Operating margin was -21.8%, net loss $1.8M (18.8% of revenue).
Sunshine Biopharma, Q2 2025: revenue $9.4M (+1% year over year), operating margin -21.8%, net loss $1.8M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.4M | +6% | +1% |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$1.8M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $9.4M in Q2 2025, up 1% year over year and up 6% from the previous quarter.
Gross margin was 36.4%, up 11.0 points from a year earlier. Operating costs exceeded revenue by $2.1M, an operating margin of -21.8%. Operating expenses grew 51% against revenue growth of 1%. The quarter ended with a net loss of $1.8M, wider than the previous quarter's $1.2M loss.
Operating cash flow was −$1.3M. Non-cash charges added back $72K of depreciation and amortization. Working capital and other items added $425K. Capital expenditures of $160K exceeded it, leaving free cash flow of −$1.4M.
Questions
What was Sunshine Biopharma's revenue in the second quarter 2025?
Sunshine Biopharma (SBFM) reported revenue of $9.4M for the second quarter 2025 (Q2 2025), +1% from a year earlier and +6% from the quarter before.
Was Sunshine Biopharma profitable in the second quarter 2025?
Operating loss was $2.1M (-21.8% of revenue) and net loss $1.8M.
Source: Sunshine Biopharma 10-Q on SEC EDGAR.